The November PBAC outcomes have revealed an unwelcome twist for a cystic fibrosis therapy, hope for young people suffering from a rare disease, and the reality that some companies are probably already dealing with the flow-on consequences of next April's 'catch-up' statutory price reductions. …
November outcomes confounded by next April's 'catch-up' reductions
December 19, 2022 Latest NewsBioPharma
Latest Video
New Stories
-
Dimerix says first ACTION3 trial site activated in Japan and first milestone payment triggered
May 30, 2025 - - Australian Biotech -
Arrotex Pharmaceuticals appointed exclusive partner for Juniper Biologics
May 29, 2025 - - Latest News -
TGA approves new therapy for children with growth hormone deficiency
May 29, 2025 - - Latest News -
AbbVie Australia appoints Dr Carly Levetan associate medical director
May 29, 2025 - - Latest News -
For patients, it's about understanding their experience and accessing the touchpoints
May 29, 2025 - - Latest News -
Priceline Pharmacy launches annual event with national menopause project
May 28, 2025 - - Latest News -
Anne Ruston welcomes her reappointment to health and the addition of NDIS
May 28, 2025 - - Latest News